Immatics
gen in cohort a most frequent adverse events | Immatics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
73 of 75
Similar slides by Immatics
See diffirences between slides (animation)
Investor Presentation
November 2023
gen in all melanoma patients at most frequent adverse events so | Immatics
Related slides by other companies
Compass Therapeutics
Investor Presentation
May 2022
phase combination safety data | Compass Therapeutics
Kymera
Investor Presentation
December 2023
safety summary | Kymera
MAIA Biotechnology
Investor Presentation
July 2023
thio trial patients dosed to date | MAIA Biotechnology
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase no no treatment related no aes leading to dose reduction or discontinuation no treatment related dizziness treatment related adverse events in patient all treated patients nausea alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting including source a toxicity | Nuvalent
Other recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights